Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) EBT (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed EBT for 11 consecutive years, with -$18.9 million as the latest value for Q4 2025.

  • Quarterly EBT rose 33.33% to -$18.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$91.7 million through Dec 2025, up 22.23% year-over-year, with the annual reading at -$91.7 million for FY2025, 21.82% up from the prior year.
  • EBT hit -$18.9 million in Q4 2025 for Seres Therapeutics, up from -$21.9 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $68.3 million in Q3 2021 to a low of -$71.5 million in Q1 2023.
  • Historically, EBT has averaged -$27.9 million across 5 years, with a median of -$31.0 million in 2024.
  • Biggest five-year swings in EBT: surged 322.87% in 2021 and later plummeted 1495.49% in 2023.
  • Year by year, EBT stood at -$49.7 million in 2021, then soared by 95.58% to -$2.2 million in 2022, then tumbled by 1495.49% to -$35.1 million in 2023, then increased by 18.99% to -$28.4 million in 2024, then skyrocketed by 33.33% to -$18.9 million in 2025.
  • Business Quant data shows EBT for MCRB at -$18.9 million in Q4 2025, -$21.9 million in Q3 2025, and -$24.3 million in Q2 2025.